GREENVILLE, S.C.--(BUSINESS WIRE)--Kiyatec, leaders in functional precision oncology, today announced the publication of a pivotal study in Scientific Reports highlighting the impact of the 3D Predict Glioma test on improving survival outcomes for patients with HGG. The study, titled “Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma,” presents compelling evidence that the 3D Predict Glioma test can significantly extend progression-free survival and overall survival in patients by accurately predicting their response to the standard chemotherapeutic regimen.
High-grade gliomas, including glioblastoma (GBM), are among the most aggressive and deadly brain cancers and have limited treatment options and historically poor prognoses. Despite advances in understanding these tumors, treatment strategies have largely remained unchanged, with most patients receiving a one-size-fits-all approach that includes radiation and temozolomide (TMZ). The 3D Predict Glioma test, developed by Kiyatec, offers a novel, personalized approach by evaluating the response of patients’ tumor tissues to chemotherapy drugs, including TMZ, before therapy begins.
“Our study has shown that the 3D Predict Glioma test is not only a prognostic tool but a critical decision-making aid for clinicians managing patients with high-grade gliomas,” said Analiz Rodriguez, MD, PhD, MBA, FAANS, a lead author of the study and Director of Neurosurgical Oncology at the University of Arkansas for Medical Sciences. “Patients whose tumors were predicted to respond to temozolomide using our test had significantly longer progression-free and overall survival compared to those predicted not to respond. There is promise that 3D Predict may be better than currently used clinical biomarkers for standard of care; it’s poised to change the treatment landscape for glioma patients.”
The prospective, observational study enrolled 102 patients with newly diagnosed HGG from multiple centers across the United States. The study found that patients identified as responders by the 3D Predict Glioma test had a median progression-free survival increase of 5.8 months and an overall survival increase of 7.6 months compared to nonresponders. These improvements were consistent across multiple subgroups, including GBM and MGMT unmethylated glioblastoma, a particularly challenging subgroup to treat.
Notably, the test’s ability to predict response was independent of traditional biomarkers such as MGMT promoter methylation, which has been used for two decades to guide glioma treatment. The study underscores the potential of the 3D Predict Glioma test to provide a more nuanced and accurate prediction of patient outcomes, allowing for more personalized treatment decisions that could spare patients from ineffective therapies and guide them toward more promising options, including clinical trials.
“The publication of this study represents a significant milestone for Kiyatec and the broader field of functional precision oncology,” said Eric Perreault, CEO of Kiyatec. “Our 3D Predict Glioma test is paving the way for a new era of individualized treatment for patients with high-grade glioma, offering hope where there was previously very little.”
The study is available online in Scientific Reports. For more information about Kiyatec and the 3D Predict Glioma test, please visit www.Kiyatec.com.
About Kiyatec
Kiyatec is a leading functional precision oncology company whose groundbreaking 3D Predict technology provides accurate, patient-specific predictions of drug response, enabling oncologists to make informed treatment decisions. They currently offer clinical testing for high-grade glioma and are poised to offer testing for ovarian cancer in their CLIA-certified laboratory. Kiyatec’s mission is to provide confidence to patients and oncologists in their life-changing cancer therapy decisions by delivering actionable insights through innovative ex vivo testing solutions.
